Comparative pharmacokinetics of N^ω-hydroxy-nor-L-arginine, an arginase inhibitor, after single-dose intravenous, intraperitoneal and intratracheal administration to brown Norway rats

References

• Abe M, Hayashi Y, Murai A, et al. (2006). Effects of inducible nitric oxide synthase inhibitors on asthma depending on administration schedule. Free Radical Biol Med 40:1083–95
   PubMed Web of Science ®Google Scholar
• Bagnost T, Berthelot A, Bouhaddi M, et al. (2008). Treatment with the arginase inhibitor N-omega-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 26:1110–18
   PubMedGoogle Scholar
• Bagnost T, Ma L, da Silva R, et al. (2010). Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 87:569–77
   PubMed Web of Science ®Google Scholar
• Bratt J, Franzi L, Linderholm AO, et al. (2010). Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol 242:1–8
   PubMed Web of Science ®Google Scholar
• Cama E, Pethe S, Boucher J, et al. (2004). Inhibitor coordination interactions in the binuclear manganese cluster of arginase. Biochemistry 43:8987–99
   PubMed Web of Science ®Google Scholar
• Clement B, Kunze T, Heberling S. (2006). Reduction of N(omega)-hydroxy-L-arginine to L-arginine by pig liver microsomes mitochondria and human liver microsomes. Biochem Biophys Res Commun 349:869–73
   PubMed Web of Science ®Google Scholar
• Cryan S, Sivadas N, Garcia-Contreras L. (2007). In vivo animal models for drug delivery across the lung mucosal. Adv Drug Deliv Rev 59:1133–51
   PubMed Web of Science ®Google Scholar
• Di Costanzo L, Ilies M, Thorn K, Christianson D. (2010). Inhibition of human arginase I by substrate and product analogues. Arch Biochem Biophys 496:101–8
   PubMed Web of Science ®Google Scholar
• Getz G, Reardon C. (2006). Arginine/arginase NONONO. Arterioscler Thromb Vasc Biol 26:237–9
   PubMed Web of Science ®Google Scholar
• Gonda I. (2006). Systemic delivery of drugs to humans via inhalation. J Aerosol Med Deposit Clearance Effects Lung 19:47–53
   PubMedGoogle Scholar
• Grönros J, Jung C, Lundberg J, et al. (2011). Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circulat Physiol 300:H1174–81
   Web of Science ®Google Scholar
• Gruenewald S, Wahl B, Bittner F, et al. (2008). The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs. J Med Chem 51:8173–7
   PubMed Web of Science ®Google Scholar
• Havemeyer A, Bittner F, Wollers S, et al. (2006). Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. J Biol Chem 281:34796–802
   PubMed Web of Science ®Google Scholar
• Hroch M, Havlinova Z, Nobilis M, Chladek J. (2012). HPLC determination of arginases inhibitor N-(omega)-hydroxy-nor-L-arginine using core-shell particle column and LC-MS/MS identification of principal metabolite in rat plasma. J Chromatogr B Anal Technol Biomed Life Sci 880:90–9
   PubMed Web of Science ®Google Scholar
• Jeyabalan G, Klune J, Naka A, et al. (2008). Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide Biol Chem 19:29–35
   PubMed Web of Science ®Google Scholar
• Jung C, Gonon A, Sjoquist P, et al. (2010). Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 85:147–54
   PubMed Web of Science ®Google Scholar
• Kitowska K, Zakrzewicz D, Konigshoff M, et al. (2008). Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:L34–45
   Web of Science ®Google Scholar
• Kotthaus J, Wahl B, Havemeyer A, et al. (2011). Reduction of N-omega-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC). Biochem J 433:383–91
   PubMed Web of Science ®Google Scholar
• Krotova K, Patel JM, Block ER, Zharikov S. (2010). Endothelial arginase II responds to pharmacological inhibition by elevation in protein level. Mol Cell Biochem 343:211–16
   PubMed Web of Science ®Google Scholar
• Maarsingh H, Dekkers B, Zuidhof A, et al. (2011). Increased arginase activity contributes to airway remodelling in chronic allergic asthma. Eur Respirat J 38:318–28
   PubMed Web of Science ®Google Scholar
• Maarsingh H, Zaagsma J, Meurs H. (2009). Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 158:652–64
   PubMed Web of Science ®Google Scholar
• Maarsingh H, Zuidhof A, Bos I, et al. (2008). Arginase inhibition protects against allergen-induced airway obstruction hyperresponsiveness and inflammation. Am J Respirat Crit Care Med 178:565–73
   PubMed Web of Science ®Google Scholar
• Mansuy D, Boucher J. (2004). Alternative nitric oxide-producing substrates for no synthases. Free Radical Biol Med 37:1105–21
   PubMed Web of Science ®Google Scholar
• Meurs H, Hamer M, Pethe S, et al. (2000). Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity. Br J Pharmacol 130:1793–8
   PubMed Web of Science ®Google Scholar
• Meurs H, McKay S, Maarsingh H, et al. (2002). Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol 136:391–8
   PubMed Web of Science ®Google Scholar
• Moali C, Boucher JL, Sari MA, et al. (1998). Substrate specificity of NO synthases: detailed comparison of L-arginine homo-L-arginine their N-omega-hydroxy derivatives and N-omega-hydroxynor-L-arginine. Biochemistry 37:10453–60
   PubMed Web of Science ®Google Scholar
• NIH Publication. (1996). Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources. Maryland, USA: NIH
   Google Scholar
• North M, Khanna N, Marsden P, et al. (2009). Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. Am J Physiol Lung Cell Mol Physiol 296:L911–20
   PubMed Web of Science ®Google Scholar
• Reid KM, Tsung A, Kaizu T, et al. (2007). Liver I/R injury is improved by the arginase inhibitor N-omega-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointestinal Liver Physiol 292:G512–17
   PubMed Web of Science ®Google Scholar
• Rotoli BM, Bussolati O, Sala R, et al. (2005). The transport of cationic amino acids in human airway cells: expression of system y(+)L activity and transepithelial delivery of NOS inhibitors. FASEB J 19:810–14
   PubMed Web of Science ®Google Scholar
• Sakagami M. (2006). In vivo in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58:1030–60
   PubMed Web of Science ®Google Scholar
• Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. (2008). Arginase and vascular aging. J Appl Physiol 105:1632–42
   PubMed Web of Science ®Google Scholar
• Takahashi N, Ogino K, Takemoto K, et al. (2010). Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model. Am J Physiol Lung Cell Mol Physiol 299:L17–24
   Web of Science ®Google Scholar
• Tenu JP, Lepoivre M, Moali C, et al. (1999). Effects of the new arginase inhibitor Nω-hydroxy-nor-l-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3:427–38
   PubMed Web of Science ®Google Scholar
• Tronde A, Norden B, Marchner H, et al. (2003). Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharmaceut Sci 92:1216–33
   PubMed Web of Science ®Google Scholar
• Vetrovsky P, Boucher JL, Schott C, et al. (2002). Involvement of NO in the endothelium-independent relaxing effects of N-omega-hydroxy-L-arginine and other compounds bearing a C=NOH function in the rat aorta. J Pharmacol Exp Therapeut 303:823–30
   PubMed Web of Science ®Google Scholar
• Vonk J, Postma D, Maarsingh H, et al. (2010). Arginase 1 and arginase 2 variations associate with asthma asthma severity and beta(2) agonist and steroid response. Pharmacogenet Genom 20:179–86
   PubMed Web of Science ®Google Scholar
• Warnken M, Haag S, Matthiesen S, et al. (2010). Species differences in expression pattern of arginase isoenzymes and differential effects of arginase inhibition on collagen synthesis in human and rat pulmonary fibroblasts. Naunyn-Schmiedebergs Arch Pharmacol 381:297–304
   PubMed Web of Science ®Google Scholar
• Zimmermann N, King N, Laporte J, et al. (2003). Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 111:1863–74
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Rothenberg ME. (2006). The arginine-arginase balance in asthma and lung inflammation. Eur J Pharmacol 533:253–62
   PubMed Web of Science ®Google Scholar